Primary liver cancer and advanced hepatobiliary malignancies represent a growing global health challenge, driven by chronic liver disease, viral hepatitis, and metabolic disorders. Early detection remains difficult, and many patients present with advanced disease. Advances in imaging, molecular profiling, and staging systems have improved diagnostic accuracy and treatment planning. Therapeutic options now include locoregional therapies, systemic targeted agents, immunotherapy, and combination approaches. Multidisciplinary care involving hepatology, oncology, surgery, and interventional radiology is essential for optimal management. Ongoing research focuses on identifying predictive biomarkers, overcoming treatment resistance, and improving survival in advanced disease. This topic explores evolving strategies in hepatobiliary oncology, emphasizing precision medicine and integrated care models.
Title : Gastroenterology viewed through a glass darkly: An IDI perspective
Gilles R G Monif, University of Florida, United States
Title : The psychology of disorders of gut-brain interactions
Tracy E Hill, Ph.D. & Associates LLC, United States
Title : How epigastric impedance would radically change gastric medicine
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Role of Pregnancy (P) and breastfeeding on Gallstones (GS) related Acute Pancreatitis (AP)
Alberto Maringhini, La Maddalena, Italy
Title : From the birth of atoms to life: Iodine and caesium, angels and demons of evolutionary biology, in pancreatic cancer and diabetes
Venturi Sebastiano, AUSL-ROMAGNA, Italy
Title : The IL17REL gene encodes a decoy receptor of IL-17 family cytokines to control gut inflammation
Youcun Qian, Shanghai Institute of Nutrition and Health, China